H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the top long-term biotechnology stocks to buy. On October 14, H.C. Wainwright reaffirmed its Buy rating and $50 price target on Assembly Biosciences (NASDAQ:ASMB) following the company’s presentation of interim data for ABI-5366, a long-acting oral treatment for recurrent genital herpes.

H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data

Source:unsplash

Presented data showed strong antiviral activity, favorable tolerability, and a dosing profile suitable for weekly or monthly administration. The firm views these results as a key validation of Assembly’s helicase-primase inhibitor platform and believes they reduce the risk of advancing ABI-5366 into Phase 2 trials. The company plans to initiate Phase 2 clinical studies by mid-2026, signaling continued progress in its antiviral pipeline.

Assembly Biosciences, Inc. (NASDAQ:ASMB) is a biotechnology company that develops and commercializes small-molecule therapies for serious viral diseases, with a particular focus on chronic hepatitis B virus (HBV) and herpesviruses.

While we acknowledge the potential of ASMB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ASMB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.